| __timestamp | ImmunityBio, Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4326000 | 10337679 |
| Thursday, January 1, 2015 | 226206000 | 18187286 |
| Friday, January 1, 2016 | 94391000 | 24758063 |
| Sunday, January 1, 2017 | 53821000 | 23666957 |
| Monday, January 1, 2018 | 35463000 | 30099855 |
| Tuesday, January 1, 2019 | 46456000 | 64947625 |
| Wednesday, January 1, 2020 | 71318000 | 186363444 |
| Friday, January 1, 2021 | 135256000 | 272611040 |
| Saturday, January 1, 2022 | 102708000 | 358782000 |
| Sunday, January 1, 2023 | 129620000 | 409864000 |
Data in motion
In the competitive landscape of biotechnology, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Intra-Cellular Therapies, Inc. and ImmunityBio, Inc. over the past decade. From 2014 to 2023, Intra-Cellular Therapies, Inc. has seen a staggering increase in SG&A expenses, growing nearly 40 times from 2014 to 2023. In contrast, ImmunityBio, Inc. experienced a more volatile trajectory, with a peak in 2015 and fluctuations thereafter. By 2023, Intra-Cellular Therapies, Inc.'s SG&A expenses were approximately 3.2 times higher than those of ImmunityBio, Inc. This trend highlights the aggressive expansion and operational strategies of Intra-Cellular Therapies, Inc., positioning it as a formidable player in the biotech sector. Investors and stakeholders should consider these financial dynamics when evaluating potential growth and investment opportunities.
Breaking Down SG&A Expenses: Johnson & Johnson vs Intra-Cellular Therapies, Inc.
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or ImmunityBio, Inc.
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs ImmunityBio, Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. and Dr. Reddy's Laboratories Limited: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Catalent, Inc.
Intra-Cellular Therapies, Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
Intra-Cellular Therapies, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing ImmunityBio, Inc. and Supernus Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: ImmunityBio, Inc. vs Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing ImmunityBio, Inc. and MiMedx Group, Inc.